Table 2.
DAOCs in HIT
| Reference | Study (N) | HIT Dx | DOAC | Dose (mg) | Other AC | Outcomes |
|---|---|---|---|---|---|---|
| 51 | Case series* (22) | ELISA/SRA+ (20) | Dabigatran (6) | 150 twice daily | Initial argatroban | New DVT (5) |
| Clinical Dx (2) | Rivaroxaban (11) | 20 daily | SVT (2) | |||
| — | Apixaban (5) | 5 twice daily | Deaths (6)† | |||
| 52 | Prospective cohort (12) | SRA+ | Rivaroxaban | 15 twice daily → 20 daily | Initial fondaparinux (6) | VTE (1) |
| Transitioned to fondaparinux‡ (1) | BKA (1) | |||||
| Deaths (4)† | ||||||
| Major bleeding‡ (1) | ||||||
| 53 | Case series (3) | ELISA+ | Rivaroxaban | 15 twice daily → 20 daily | Transitioned to warfarin (1) | Platelet recovery, no thrombosis |
| 15 twice daily | ||||||
| 10 daily§ |
AC, anticoagulant; BKA, below-knee amputation; DVT, deep vein thrombosis; DX, diagnosis; SVT, supraventricular tachycardia; VTE, venous thromboembolism.
*Retrospective case series with prospective determination of outcomes.
†Deaths were not due to thrombosis but to the underlying disease states, including cancer, heart failure, renal failure, systemic sclerosis, sepsis, and end-stage chronic obstructive pulmonary disease.
‡One patient transitioned to fondaparinux due to elevated hepatic enzymes.
§Renal-adjusted dose in a dialysis-dependent patient.